Advertisement
UK markets close in 3 hours 46 minutes
  • FTSE 100

    8,296.37
    +82.88 (+1.01%)
     
  • FTSE 250

    20,399.57
    +235.03 (+1.17%)
     
  • AIM

    777.38
    +5.85 (+0.76%)
     
  • GBP/EUR

    1.1650
    -0.0010 (-0.08%)
     
  • GBP/USD

    1.2543
    -0.0021 (-0.16%)
     
  • Bitcoin GBP

    50,757.80
    -318.39 (-0.62%)
     
  • CMC Crypto 200

    1,326.85
    -38.27 (-2.80%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CRUDE OIL

    78.25
    -0.23 (-0.29%)
     
  • GOLD FUTURES

    2,324.60
    -6.60 (-0.28%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • DAX

    18,279.96
    +104.75 (+0.58%)
     
  • CAC 40

    8,024.25
    +27.61 (+0.35%)
     

Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance

Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance

Boston Scientific’s (BSX) Cardiovascular segment is comprised of cardiology and peripheral interventions. Its operating income was $290 million, or 31.1% of the segment’s revenues, in Q1 2018, up from $233 million, or 27.3% of the segment’s revenues, in Q1 2017. Worldwide interventional cardiology sales increased 10%, from $590 million in Q1 2017 to $645 million in Q1 2018.